STOCK TITAN

Quanterix SEC Filings

QTRX NASDAQ

Welcome to our dedicated page for Quanterix SEC filings (Ticker: QTRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Trying to decode Quanterix’s R&D spend, grant revenue and Simoa roll-out plans inside a 200-page disclosure can slow any analyst. That’s why our platform keeps Quanterix SEC filings explained simply. Stock Titan’s AI pinpoints the assays driving growth and flags accounting nuances the moment each document hits EDGAR.

Need the numbers fast? Our dashboard links every Quanterix quarterly earnings report 10-Q filing to AI commentary on instrument placements and consumable margins, while a single click delivers a Quanterix annual report 10-K simplified summary that highlights R&D burn and royalty obligations. Form 8-K alerts—think FDA assay clearances—arrive under the heading Quanterix 8-K material events explained. Executive pay questions? Open the latest Quanterix proxy statement executive compensation note and see side-by-side trend charts.

Real-time compliance matters too. Track every Quanterix insider trading Form 4 transactions notice or set instant e-mail triggers for Quanterix Form 4 insider transactions real-time. Use our heat-map to spot cluster buying, then overlay it with Quanterix earnings report filing analysis for context. Whether you’re understanding Quanterix SEC documents with AI before a funding round or reviewing Quanterix executive stock transactions Form 4 ahead of board meetings, the platform supplies complete coverage—10-K, 10-Q, 8-K, Form 4, S-1 and more—updated the instant Quanterix uploads to EDGAR.

Rhea-AI Summary

Quanterix Corporation (QTRX) – Form 4 insider transaction

Director Sarah E. Hlavinka reported the acquisition of 2,615 shares of Quanterix common stock on 07/01/2025. The shares were granted in lieu of cash fees for Board and committee service for the second quarter of 2025 and were valued at the Nasdaq closing price of $6.69 on the grant date. No shares were sold.

After the award, Hlavinka’s total beneficial ownership stands at 60,070 shares, which includes 7,435 restricted stock units. All holdings are reported as directly owned. The filing, signed by Brian Keane under power of attorney on 07/03/2025, involves a single reporting person who serves solely as a director. No derivative securities or additional transactions were disclosed.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Sempra (SRE) – Form 4 insider filing: Director Jack T. Taylor reported acquiring 164.09 phantom shares of Sempra common stock on 01 July 2025 as part of routine board compensation. Each phantom share converts 1-for-1 into common stock upon distribution. Following the grant, Taylor now holds 40,321.76 phantom shares, of which 1,863.44 are unvested and subject to forfeiture if service ends under certain conditions. No open-market purchases or sales of Sempra common shares were disclosed, and there were no changes to direct share ownership.

Because the transaction is compensation-related and involves a relatively small number of derivative units compared with Taylor’s existing position, the filing is considered routine and does not materially alter the company’s ownership structure.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

On 06/30/2025, WESCO International (WCC) Executive Vice President & Chief Human Resources Officer Christine Ann Wolf reported the acquisition of 7.7069 shares of common stock through dividend-equivalent rights (DERs) attached to existing restricted stock units. The shares were credited at a price of $0.00, reflecting automatic reinvestment of the company’s quarterly dividend.

After this routine accrual, Wolf’s direct holdings increased to 30,188.2811 shares. No shares were sold and no other derivative transactions were reported. Given the immaterial size of the acquisition—well below 0.01% of WESCO’s outstanding shares—the filing is viewed as a normal administrative adjustment rather than a meaningful indicator of insider sentiment or future company performance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Insider transaction disclosure: Aware Inc. (AWRE) director Gary Evee filed a Form 4 reporting the acquisition of 23,490 shares of common stock on 07/01/2025. The transaction is coded “M,” denoting the exercise or conversion of a derivative security under SEC rules, and carries an exercise price of $0. After the transaction, Evee’s direct beneficial ownership increases to 99,557 shares. No dispositions, sales, or additional derivative securities were reported, and no price was paid in open-market transactions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Zscaler, Inc. (ZS) has filed a Form 144 indicating a proposed insider sale of common stock. The filing covers the potential sale of 56,428 shares with an aggregate market value of approximately $17.45 million. The shares are expected to be sold on or about 07/02/2025 through Morgan Stanley Smith Barney LLC on the NASDAQ exchange. As disclosed, Zscaler has 155,695,672 shares outstanding; therefore, the planned sale represents roughly 0.036 % of total shares.

The seller, Remo E. Canessa, previously sold 3,684 shares on 06/17/2025 for gross proceeds of $1.12 million. The current Form 144 aggregates shares acquired via restricted stock awards, performance shares, and an employee stock-purchase plan between 2018-2022. No gifts were involved and prior purchases were made either without cash consideration (share grants) or with cash (ESPP shares).

Form 144 is a notice of intent; it does not guarantee that the sale will occur, but it signals insider intent and allows the market to anticipate potential share supply. The filer attests that no material non-public adverse information is known and acknowledges Rule 144 and 10b5-1 representations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

On June 26, 2025, Quanterix Corporation (QTRX) filed an 8-K to announce logistics for its 2025 Annual Meeting of Stockholders. The meeting will be held virtually on September 23, 2025 at 9:00 a.m. ET. Because the meeting date falls more than 30 days after the 2024 meeting anniversary, the company has reset key shareholder deadlines:

  • Rule 14a-8 proposals must be received by the corporate secretary by July 11, 2025.
  • Bylaw-based business or director nominations (outside Rule 14a-8) also require written notice by July 11, 2025.
  • Universal proxy notification (Rule 14a-19) is due by July 25, 2025.

No financial results, strategic transactions or operational updates were disclosed. The filing is procedural, ensuring compliance with SEC rules and providing investors sufficient time to submit proposals or nominations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report

FAQ

What is the current stock price of Quanterix (QTRX)?

The current stock price of Quanterix (QTRX) is $6.98 as of July 3, 2025.

What is the market cap of Quanterix (QTRX)?

The market cap of Quanterix (QTRX) is approximately 255.3M.

What is the core technology behind Quanterix?

Quanterix is based on ultra-sensitive digital immunoassay platforms using Simoa technology, which enables detection of protein biomarkers at extremely low concentrations.

Which industries does Quanterix primarily serve?

Quanterix serves the life sciences research and clinical diagnostics industries, offering solutions that enhance biomarker detection and precision health applications.

How does Quanterix differentiate itself from traditional immunoassays?

By leveraging cutting-edge digital immunoassay technology, Quanterix offers significantly higher sensitivity than traditional analog immunoassays, making it possible to detect biomarkers at much lower levels.

What types of products and services does Quanterix offer?

The company offers a range of digital immunoassay instruments, assay kits, lab-developed tests, and custom assay development services designed for precise biomarker detection.

What is the significance of Quanterix's exclusive intellectual property?

The exclusive licensing of a robust intellectual property portfolio, developed through academic research, reinforces Quanterix's technological credibility and underpins its advanced diagnostics platform.

Who are the primary customers of Quanterix?

Quanterix primarily serves research laboratories, clinical diagnostic centers, and biotechnology companies that require highly sensitive and precise biomarker detection capabilities.

How does Quanterix contribute to precision health?

By enabling the detection of low-abundance biomarkers, Quanterix's technology aids in early diagnosis and personalized treatment decisions, which are critical components of precision health.

What makes Quanterix a reliable resource in the diagnostics industry?

Its deep technological innovation, comprehensive product portfolio, and commitment to scientific excellence position Quanterix as a trustworthy and unbiased provider of advanced diagnostic solutions.
Quanterix

NASDAQ:QTRX

QTRX Rankings

QTRX Stock Data

255.28M
35.87M
14.82%
95.77%
6.05%
Medical Devices
Laboratory Analytical Instruments
Link
United States
BILLERICA